Marc Eleveld

Mr. Marc Eleveld

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2021 in Viruses
Verified
Journal Article
Open access
PDF file
FVFinny S. Varghese
Finny S. Varghese
EWEsther Van Woudenbergh
Esther Van Woudenbergh
GOGijs Overheul
Gijs Overheul
MEMarc Eleveld
Marc Eleveld
LKLisa Kurver
Lisa Kurver
RRRonald Van Rij
Ronald Van Rij
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a new human pathogen in late 2019 and it has infected over 100 million people in less than a year. There is a clear need for effective antiviral drugs to complement current preventive measures, including vaccines. In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2. Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, which was originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations. Time-of-addition studies indicated that berberine acts on the late stage of the viral life cycle. In agreement, berberine mildly affected viral RNA synthesis, but it strongly reduced infectious viral titers, leading to an increase in the particle-to-pfu ratio. In contrast, obatoclax acted at the early stage of the infection, which is in line with its activity to neutralize the acidic environment in endosomes. We assessed infection of primary human nasal epithelial cells that were cultured on an air-liquid interface and found that SARS-CoV-2 infection induced and repressed expression of specific sets of cytokines and chemokines. Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells. We propose berberine and obatoclax as potential antiviral drugs against SARS-CoV-2 that could be considered for further efficacy testing.

21 August 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AZAnne Zeddeman
Anne Zeddeman
ESEvi van Schuppen
Evi van Schuppen
KKKristianne E. Kok
Kristianne E. Kok
MGMarjolein van Gent
Marjolein van Gent
KHKees J. Heuvelman
Kees J. Heuvelman
DDDimitri A. Diavatopoulos
Dimitri A. Diavatopoulos
Bordetella pertussis vaccine escape mutants that lack expression of the pertussis antigen pertactin (Prn) have emerged in vaccinated populations in the last 10–20 years. Additionally, clinical isolates lacking another acellular pertussis (aP) vaccine component, filamentous hemagglutinin (FHA), have been found sporadically. Here, we show that both whole-cell pertussis (wP) and aP vaccines induced protection in the lungs of mice, but that the wP vaccine was more effective in nasal clearance. Importantly, bacterial populations isolated from the lungs shifted to an FHA-negative phenotype due to frameshift mutations in the fhaB gene. Loss of FHA expression was strongly selected for in Prn-deficient strains in the lungs following aP but not wP vaccination. The combined loss of Prn and FHA led to complete abrogation of bacterial surface binding by aP-induced serum antibodies. This study demonstrates vaccine- and anatomical site-dependent adaptation of B. pertussis and has major implications for the design of improved pertussis vaccines.

23 March 2026 in The Lancet Microbe
Verified
Journal Article
Open access
HGHans de Graaf
Hans de Graaf
DGDiane F Gbesemete
Diane F Gbesemete
AHAlison R Hill
Alison R Hill
JFJaneri Fröberg
Janeri Fröberg
MIMuktar M Ibrahim
Muktar M Ibrahim
RRRobert C Read
Robert C Read
Cyclical epidemics of pertussis, also known as whooping cough, continue to occur despite vaccination, because current vaccines fail to suppress colonisation by, and transmission of, the causative agent Bordetella pertussis. We aimed to show the safety of B pertussis controlled human infection delivered in an outpatient setting, as well as identify immunological correlates of protection against B pertussis colonisation, to guide the future development of pertussis vaccines. This open-label, phase 1, controlled human infection study was conducted at University Hospital Southampton, Southampton, UK. Healthy volunteers aged 18-55 years who had received a whole-cell pertussis vaccine in childhood were inoculated intranasally with 105 colony-forming units of wild-type B pertussis strain B1917. Volunteers were monitored as outpatients for 28 days to assess safety, colonisation, and B pertussis-specific immunological parameters. Individuals who shared a bedroom with inoculated volunteers were enrolled to measure transmission to close contacts. After approximately 90 days, volunteers who agreed to participate in a rechallenge phase of the study were re-inoculated with the same dose of B pertussis. Volunteers received azithromycin 14 days after each inoculation. The primary objective was to assess the safety of delivering this controlled human infection model on an outpatient basis; safety endpoints were the occurrence of possible or confirmed pertussis and unsolicited or serious adverse events. Secondary objectives were the assessment of immunological biomarkers of protection from colonisation and the assessment of transmission from volunteers to close contacts. All volunteers who received the inoculum were included in the safety analysis, and all participants who completed follow-up to day 14 were included in the per-protocol population for colonisation and immunological analysis. This trial is registered at ClinicalTrials.gov, NCT03751514, and is ongoing. Between Aug 29, 2019 and March 6, 2023, 77 volunteers were screened and 51 were enrolled and inoculated, of whom 50 completed follow-up to day 14 post-inoculation. 20 (40%) of these 50 volunteers became colonised with B pertussis. One volunteer developed symptoms suggestive of possible pertussis after initial inoculation; this volunteer tested negative for B pertussis throughout the study and all symptoms resolved within 4 days. Adverse events were mostly mild to moderate, with no significant increase in the reporting of any individual symptom by colonised volunteers. All unsolicited adverse events were assessed as either unlikely to be related or unrelated to B pertussis infection, with no increase in the frequency of these events seen in colonised volunteers. There were no serious adverse events and no treatment-related deaths. Compared with those who became colonised with B pertussis, non-colonised volunteers had significantly higher pre-inoculation serum IgG antibody concentrations against several acellular pertussis vaccine antigens (pertussis toxin [p=0·028], pertactin [p=0·037], and filamentous haemagglutinin [p=0·024]); higher nasal (p=0·022) and serum (p=0·044) IgA antibody concentrations against whole B pertussis; higher serum IgA antibody concentrations specific to filamentous haemagglutinin (p=0·024); and higher peripheral T-helper (Th)-22-cell responses to pertussis toxin (p=0·0045) and filamentous haemagglutinin (p=0·029). After inoculation, only colonised volunteers showed seroconversion, IgA and IgG binding to B pertussis, and increases in B pertussis-specific IgG-secreting memory B-cell frequencies by day 28. Th17 responses to pertussis toxin were increased (p=0·039) and Th22 responses to filamentous haemagglutinin were decreased (p=0·014) in non-colonised volunteers. Of the 13 volunteers who became colonised after initial inoculation and were re-inoculated, only one (8%) became colonised after re-inoculation. Transmission from volunteers to 14 enrolled individuals with whom they shared a bedroom was not detected. Our findings suggest that controlled human infection with B pertussis in an outpatient setting is safe. Higher humoral and CD4+ T-cell responses with specificity to acellular pertussis vaccine antigens are associated with protection against colonisation by B pertussis after experimental challenge. This technique could enable the testing of potential novel vaccines or formulations for sustained protection against infection and transmission. EU Horizon 2020 (Innovative Medicines Initiative) and the National Institute for Health and Care Research Southampton Biomedical Research Centre.

24 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
FVFinny S. Varghese
Finny S. Varghese
EWEsther Van Woudenbergh
Esther Van Woudenbergh
GOGijs Overheul
Gijs Overheul
MEMarc Eleveld
Marc Eleveld
LKLisa Kurver
Lisa Kurver
RRRonald Van Rij
Ronald Van Rij
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a new human pathogen in late 2019 and has infected an estimated 10% of the global population in less than a year. There is a clear need for effective antiviral drugs to complement current preventive measures including vaccines. In this study, we demonstrate that berberine and obatoclax, two broad-spectrum antiviral compounds, are effective against multiple isolates of SARS-CoV-2. Berberine, a plant-derived alkaloid, inhibited SARS-CoV-2 at low micromolar concentrations and obatoclax, originally developed as an anti-apoptotic protein antagonist, was effective at sub-micromolar concentrations. Time-of-addition studies indicated that berberine acts on the late stage of the viral life cycle. In agreement, berberine mildly affected viral RNA synthesis, but strongly reduced infectious viral titers, leading to an increase in the particle-to-pfu ratio. In contrast, obatoclax acted at the early stage of the infection, in line with its activity to neutralize the acidic environment in endosomes. We assessed infection of primary human nasal epithelial cells cultured on an air-liquid interface and found that SARS-CoV-2 infection induced and repressed expression of a specific set of cytokines and chemokines. Moreover, both obatoclax and berberine inhibited SARS-CoV-2 replication in these primary target cells. We propose berberine and obatoclax as potential antiviral drugs against SARS-CoV-2 that could be considered for further efficacy testing.

24 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
SPSherin Pojar
Sherin Pojar
ABAlan Basset
Alan Basset
JGJenna Gritzfeld
Jenna Gritzfeld
ENElissavet Nikolaou
Elissavet Nikolaou
SSSaskia van Selm
Saskia van Selm
DFDaniela M. Ferreira
Daniela M. Ferreira
Summary: Colonization efficiency varies considerably between Streptococcus pneumoniae (pneumococcus) strains. The microbial characteristics that influence those differences are still largely unknown. Here, we report rates and kinetics of colonization of four pneumococcal strains upon experimental human pneumococcal challenge. Healthy adults were intranasally challenged with one of four pneumococcal strains (serotype/clonal name: 6B/BHN418, 15B/SH8286, 23F/P1121 and 23F/P833) over a range of doses. Maximum colonization achieved was 60%, 31%, 16% and 10%, respectively. Density and duration of colonization did not differ significantly between the tested strains. We further evaluated murine colonization, non-opsonic neutrophil mediated killing, epithelial cell adherence and average chain length of these four pneumococcal strains. Of these, only chain length was found to be associated with colonization efficiency in the human challenge model. Our data demonstrate that colonization rates following experimental challenge vary with the strain used and suggest that efficiency in colonization is related to pneumococcal chain length.

18 February 2026 in Journal of Infection
Verified
Journal Article
Open access
LBLucille van Beek
Lucille van Beek
SCSuzanne E.T. Comans
Suzanne E.T. Comans
KTKoen Totté
Koen Totté
JFJaneri Fröberg
Janeri Fröberg
CJChrista E. van der Gaast-De Jongh
Christa E. van der Gaast-De Jongh
DDDimitri A. Diavatopoulos
Dimitri A. Diavatopoulos
Colonisation of the upper airways by Streptococcus pneumoniae is a prerequisite for disease development and shapes immune responses that vary between geographical settings. This first controlled human pneumococcal infection study in the Netherlands assessed colonisation, antibody responses, respiratory symptoms, and concurrent viral infections. Twenty healthy adults (19-47 years) were enrolled between May 2022 and February 2023 and inoculated intranasally with 160,000 colony forming units of S. pneumoniae serotype 6B (strain BHN418). Participants were monitored for 28 days to assess colonisation, respiratory viral infection and safety. Serum and nasal lining fluid were collected to measure IgA, IgM and IgG responses to serotype 6B polysaccharide (6B) and whole pneumococci. Eight of 20 participants (40%) became colonised. Colonised participants showed significant rises in serum and mucosal IgG and IgA to 6B, but not to pneumococci. Fifteen participants tested positive for at least one respiratory virus. Symptoms were generally mild but occurred more often in those with concurrent pneumococcal colonisation and viral infection. Colonisation rates were comparable to studies in other populations. Colonisation induced systemic and mucosal antibody responses, while viral co-infection increased symptom burden. This controlled infection study demonstrates feasibility and safety, and establishes a platform for vaccine evaluation and pneumococcal-viral interaction studies.